The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology.
No abstract available
References:
Rivero-Santana B, Saldana-Garcia J, Caro-Codon J, Zamora P, Moliner P, Martinez Monzonis A, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J 2025;46:273–84. 10.1093/eurheartj/ehae496
Zhou X, Liu Y, Shen Y, Chen L, Hu W, Yan Y, et al. Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1alpha. Eur Heart J 2024;45:2235–50. 10.1093/eurheartj/ehae188
Caller T, Rotem I, Shaihov-Teper O, Lendengolts D, Schary Y, Shai R, et al. Small extracellular vesicles from infarcted and failing heart accelerate tumor growth. Circulation 2024;149:1729–48. 10.1161/CIRCULATIONAHA.123.066911
Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J 2024;45:4414–24. 10.1093/eurheartj/ehae574
Jacobs JEJ, Greason G, Mangold KE, Wildiers H, Willems R, Janssens S, et al. Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur J Prev Cardiol 2024;31:560–6. 10.1093/eurjpc/zwad348